FDA Divulges Cosmetics Enforcement Data, Notes Hair Loss As ‘Serious’ AE
This article was originally published in The Rose Sheet
Momentum this year behind legislative proposals for cosmetics regulatory reform has prompted key Congress members to question FDA about the current oversight system. In a response to the Senate HELP Committee’s chairman, FDA provides a wealth of data on its enforcement activities and confirms hair loss as an adverse event it considers “serious,” if not one currently identified as such by MedWatch’s definition.
You may also be interested in...
Following an FDA warning letter in 2016 for an unapproved sunscreen drug product, Diamond Wipes now must answer agency concerns regarding “poor-quality water” used in its manufacturing operations. Both warnings stemmed from inspections in the wake of a 2014 product recall for mold contamination.
Locke Lord attorney Sharon Blinkoff, general counsel for the small-business trade group, says the newly introduced Safe Cosmetics Modernization Act is crafted to update cosmetics regulations without making room for oppressive oversight or a revival of the aggressively conservative FDA of decades past.
The Honest Company recalls all lots of its Organic Baby Powder following routine testing that indicated potential contamination with unsavory microorganisms. FDA scrutiny could follow.